Search This Blog

Saturday, May 16, 2026

ImmunityBio exclusive U.S. rights to Japan BCG Laboratory's Tokyo-172 BCG strain, to seek FDA approval

 

ImmunityBio secures exclusive U.S. rights to Japan BCG Laboratory's Tokyo-172 BCG strain, plans to seek FDA approval

  • Exclusive U.S. development and supply agreement covers development, importation and commercialization of the Tokyo-172 BCG product.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)